OBJECTIVES: Among the approved intravenous iron formulations, ferric carboxymaltose (Ferinject®) is the most efficacious in the treatment or prevention of iron deficiency anemia, it’s less burdensome to administer (easier and shorter time administration) and it reduces the need for expensive resource utilization like erythropoietin and blood transfusions. The objective was to develop a tool to assess the relative cost-efficiency of different intravenous iron formulations in the perspective of the Portuguese hospitals. METHODS: A fully parameterizable Microsoft® Excel based tool was developed to compare the economic efficiency of intravenous iron formulations available to the Portuguese hospitals: ferric carboxymaltose (Ferinject®); ferric hydroxide saccharose (generic and Venofer®); ferric hydroxide dextran (Cosmofer®). Economic efficiency was calculate as the balance between hospitals incurred costs relative to the number of patients to be treated, the dose and number of administrations of intravenous iron, and the need for erythropoietin and blood transfusions. The tool default values are from a literature review used to populate the model. The tool allows studying the cost and benefits of treating/preventing chronic kidney disease, inflammatory bowel disease, chemotherapy, and orthopedic surgery related anemia. RESULTS: Ferric hydroxide saccharose (generic) is to the most used and lower price intravenous iron in Portugal. Relative to generic ferric hydroxide saccharose (FHS), ferric carboxymaltose (FC) is estimated to lower mean per patient annual costs in all four anemic conditions in major hospitals: 3,087.60€ (FC) vs. 3,482.20€ (FHS) for chronic kidney disease; 2,195.75€ (FC) vs. 2,427.4€ (FHS) for inflammatory bowel disease; 3,626.17€ (FC) vs. 3,793.13€ (FHS) for chemotherapy; and 3,485.74€ (FC) vs. 3,849.47€ (FHS) for orthopedic surgery. These results were consistent irrespective of the type of hospital. CONCLUSIONS: This is a valuable tool to inform hospital decision-makers about the economic value of ferric carboxymaltose as compared to other intravenous iron formulations.